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8 The Journal of Thoracic and Cardiovbjectives: We sought to examine the effect of revascularization with coronary
rtery bypass grafting on specific causes of death in the Bypass Angioplasty
evascularization Investigation cohort. Although the effect of coronary revascular-
zation on long-term mortality has been previously described, there are limited data
escribing its effect on specific causes of death in patients with coronary artery
isease. Evaluation of cause of death might help elucidate disease mechanisms and
e useful for developing treatment strategies.
ethods: In the Bypass Angioplasty Revascularization Investigation randomized
rial and registry, 3610 patients underwent initial revascularization with coronary
rtery bypass grafting or balloon angioplasty and were followed for an average of
.7 years. Causes of all deaths were classified by an independent committee.
esults: Among 3610 revascularized patients, 2239 underwent coronary artery
ypass grafting as an initial or subsequent procedure. Over 7.7 years of follow-up,
% of all patients died of sudden cardiac death, 3% died of myocardial infarction–
elated death, 2% died of congestive heart failure and other cardiac causes, and 9%
ied of noncardiac causes. Coronary artery bypass grafting (vs no coronary artery
ypass grafting) was associated with a significantly lower risk of sudden cardiac
eath (relative risk, 0.60; P  .01) but was not significantly associated with any
ther causes of long-term mortality.
onclusions: In the Bypass Angioplasty Revascularization Investigation coronary
rtery bypass grafting significantly decreased the risk of sudden cardiac death but
ot any other cause of long-term mortality. Because major risk factors for sudden
ardiac death have historically favored a revascularization strategy of coronary
rtery bypass grafting over angioplasty, evaluation of the current practice of ex-
ending angioplasty as an alternative to coronary artery bypass grafting in similar
igh-risk subgroups is paramount.
ardiovascular disease is the leading cause of mortality in Western countries.1
The specific cause of death varies and might be the result of sudden cardiac
death, myocardial infarction (MI), or congestive heart failure (CHF). Al-
hough the effect of coronary revascularization on all-cause and cardiac mortality
as been previously described,2-5 there are limited data on the effect of revascular-
zation on specific causes of death in patients with coronary artery disease (CAD).
esults from the Coronary Artery Surgery Study6 and other studies7,8 indicate that
evascularization with coronary artery bypass grafting (CABG) might affect specific
auses of mortality, in particular sudden death. Evaluation of cause of death could
elp elucidate the mechanism of disease processes and have important implications
ascular Surgery ● July 2007
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CDor developing optimal treatment strategies for improving
ong-term survival after coronary revascularization.
The Bypass Angioplasty Revascularization Investigation
BARI) study has cause-specific death data on 3610 patients
ndergoing initial revascularization with either CABG or
ercutaneous transluminal coronary angioplasty (PTCA).2
he main finding in the BARI randomized trial was a
ignificantly lower 7-year mortality in the CABG treatment
rm compared with in the PTCA treatment arm (16% vs
9%, respectively; P  .04).9 Among patients with treated
iabetes at baseline, 7-year mortality was also significantly
ower in those randomized to CABG (24% in the CABG
reatment arm vs 44% in the PTCA treatment arm, P 
001); however, there was no treatment difference in mor-
ality among patients without diabetes (14% in the CABG
reatment arm vs 13% in the PTCA treatment arm, P .72).
urthermore, the mortality difference between PTCA and
ABG among patients with diabetes was due entirely to
ardiac deaths.10
The purpose of this article was to investigate the effect of
evascularization with CABG on specific causes of long-
erm mortality in the BARI cohort.
aterials and Methods
tudy Design
ARI is a multicenter clinical study designed to compare an initial
evascularization strategy of CABG versus PTCA on long-term
ortality in patients with multivessel coronary disease judged
uitable for both procedures. The study was institutional review
oard approved and was sponsored by the National Heart, Lung,
nd Blood Institute, which was not directly involved in the data
nterpretation for this article. A detailed description of the study
esign has been published previously.11
Participants were enrolled from 18 clinical sites in the United
tates and Canada between August 1988 and August 1991. Eligi-
ility criteria included clinically severe angina or evidence of
schemia requiring revascularization and angiographically docu-
ented CAD involving 2 or 3 vessels amenable to revasculariza-
ion. Of the 4107 eligible patients identified, 1829 provided written
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CHF  congestive heart failure
CI  confidence interval
ECG  electrocardiography
EF  ejection fraction
MI myocardial infarction
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
RR  relative risknformed consent to enroll in the clinical trial and be randomly d
The Journal of Thoracssigned to receive either CABG or PTCA. Eligible patients who
eclined randomization were given the opportunity to participate
n the BARI registry, in which the patients and their physicians
elected the initial treatment but had similar follow-up schedules
s the randomized patients. Two thousand ten patients provided
nformed consent to enroll in the BARI registry. The BARI cohort
f revascularized patients is the focus of this analysis, specifically
hose who received their assigned revascularization treatment in
he clinical trial and those who were revascularized within 3
onths of enrollment in the registry.
Identical baseline data were collected for all patients, which
nclude demographic descriptors, clinical history, 12-lead electro-
ardiographic (ECG) measurements, coronary angiographic mea-
urements, angina, functional status, medications, risk factors, and
uality of life. In this analysis ECG data are based on core
aboratory interpretation, whereas angiographic data are based on
linical site interpretation. CABG is defined as revascularization
ith CABG at any time during the BARI study. Thus, patients who
nitially received PTCA and subsequently underwent CABG dur-
ng follow-up are classified as having CABG in this analysis.
Follow-up data were obtained from clinic visits at 4 to 14
eeks and 1, 3, and 5 years and telephone contacts at 6 months and
and 4 years. After 5 years, follow-up contacts were made
nnually by telephone, and vital status was obtained for 98% of the
atients as of September 15, 1997.
lassification of Cause-of-death Outcomes
eaths were classified by an independent mortality and morbidity
lassification committee by using the following documents: death
ertificate; coroner’s report, if available; report from the clinical
ite’s principal investigator; surgical and catheterization laboratory
eports if death occurred within 30 days of a procedure; ECG and
ardiac enzyme levels measured within 24 hours of death; and
n-hospital data ascertained from medical records. Each death was
eviewed independently by 2 members of the mortality and mor-
idity classification committee and classified into one of the fol-
owing primary classifications: direct or contributory cardiac, ath-
rosclerosis-related noncardiac, noncardiac medical (eg, cancer
nd pulmonary disease), noncardiac trauma, accident, suicide,
ther, unknown, and unclassifiable causes.11 Disagreements be-
ween reviewers on the primary cause of death were resolved by
ull committee consensus.
Deaths determined to be of cardiac origin received one of the
ollowing secondary classifications: sudden death, death secondary
o MI, CHF, cardiogenic shock, unwitnessed beyond 1 hour, and
ther documented cardiac causes. Agreement between the 2 re-
iewers on the secondary classifications was not required. If re-
iewers assigned different secondary causes to the same patient
eath, the following hierarchy was applied to determine death
lassification for this analysis: unwitnessed beyond 1 hour was
referred over MI death, which was preferred over sudden death,
hich was preferred over CHF, which was preferred over other
ardiac causes. By using these classifications, the following 4 end
oints were defined for the purpose of this analysis: (1) sudden
ardiac death includes deaths within 1 hour of the onset of cardiac
ymptoms and deaths unwitnessed beyond 1 hour; (2) MI death
ncludes deaths within 30 days of documented or probable MI and
eaths resulting from cardiogenic shock; (3) CHF and other car-
ic and Cardiovascular Surgery ● Volume 134, Number 1 39
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CDiac death includes deaths as a result of CHF and all other
ocumented cardiac causes; and (4) noncardiac death includes
eaths resulting from atherosclerosis, medical- and trauma-related
oncardiac causes, accidents, suicides, and other, unknown, and
nclassifiable causes.
tatistical Analyses
aseline characteristics are presented by vital status and by cause
f death. Statistical comparisons were made between groups de-
ned by the 4 mutually exclusive causes of death (alive patients
xcluded). 2 Tests were used to compare categoric variables, and
ilcoxon nonparametric tests were used to compare continuous
ariables.
For all time-to-event analyses, the date of the initial revascu-
arization procedure was considered time zero, and patients re-
ained in the no-CABG group until the time that they received a
ABG, at which point they joined the CABG group. Cumulative
ortality rates in the CABG and no-CABG groups were estimated
y using the transient-state method12 and compared by using the
og-rank test.
Multivariate analysis was conducted with Wei-Lin-Weissfeld
ompeting-risks regression,13 an extension of the traditional Cox
roportional hazards regression that allows multiple competing
utcomes to be modeled simultaneously. Patients were considered
o be at risk for the 4 cause-specific mortality outcomes until the
ime of either censoring or death. Patients who died were consid-
red to have had an event for the specific cause of their death and
ensored for the other 3 outcomes at the time of death. An initial
ompeting-risks model was constructed to estimate the unadjusted
ffect of CABG on cause of death and to test for departures from
he proportional hazards assumption. A multivariate model was
uilt by allowing baseline predictors of mortality14 to enter by
sing forward stepwise selection (entry criterion, P  .05). The
ime-dependent CABG variable was then added to the model, and
ovariates with a P value of greater than .01 were removed by
sing backward selection. Missing values (3% for any variable)
or clinical history variables included in the final multivariate
odel were set to the mean value for continuous variables and zero
or binary variables. Differential effects of CABG on the 4 cause-
pecific mortality outcomes were tested in the multivariate model.
tatistical interactions between CABG and diabetes status on each
ause of death were also tested. In the presence of any significant
nteractions, separate multivariate models were constructed for
atients with diabetes and for those without diabetes. Lastly,
tandard Cox regression was used to estimate the independent
ffect of CABG on all-cause mortality.15
Estimates of relative risk (RR), 95% confidence intervals (CIs),
nd P values are reported. All analyses were performed with SAS
ersion 8.2 (SAS, Cary, NC).
esults
hree thousand six hundred ten BARI participants under-
ent coronary revascularization and were followed for an
verage of 7.7 years. Patients receiving CABG included
hose who received CABG as the initial revascularization (n
1517) and those who received PTCA as the initial pro-
edure and subsequently crossed over to CABG (n  722), C
0 The Journal of Thoracic and Cardiovascular Surgery ● July 22% of which occurred within 6 months of initial treatment
ith PTCA. There were 1371 patients who received only
TCA (no CABG) during 7.5 years. At the end of follow-
p, 83% of patients (n  2989) were alive, and 17% (n 
21) had died (Figure E1). Three percent (n  107) of
atients died of sudden cardiac death, 3% (n  109) died of
I, 2% (n  68) died of CHF and other cardiac causes, and
% (n 337) died of noncardiac causes. Of all deaths, 17%
ere attributed to sudden cardiac death, 18% to MI, 11% to
HF and other cardiac causes, and 54% to noncardiac
auses.
Characteristics at study entry are presented in Table 1.
mong patients who died, mean age at baseline, presence of
iabetes, history of MI, CHF, angina duration of at least 1
ear, ST-segment depression, and ejection fraction (EF) of
ess than 50% differed significantly by cause of death.
hose patients who died suddenly were younger than pa-
ients who died of other causes. Compared with surviving
atients, those who died from sudden cardiac death more
requently had EFs of less than 50%, diabetes, prior MI,
nstable angina, triple-vessel disease, and abnormalities on
aseline ECG.
nadjusted Effect of CABG on Causes of Death
nadjusted mortality rates were 17% (251/1517) among
atients who underwent CABG as the initial revasculariza-
ion, 13% (97/722) among patients who received CABG as
subsequent procedure, and 20% (273/1371) among pa-
ients who never received CABG. On the basis of transient-
tate Kaplan–Meier curves (Figure 1), noncardiac death
ates among patients who underwent CABG and those who
id not were similar throughout follow-up and were 9.7%
nd 9.9%, respectively (P  .84) at 7.5 years. Cardiac
ortality in the CABG and no-CABG groups were similar
ver time, with an early preponderance of events and a
radual increase over the remaining follow-up period.
even and a half years after initial revascularization, cardiac
eath rates in the CABG and no-CABG groups were 7.3%
nd 8.6%, respectively (P  .93).
Transient-state Kaplan–Meier estimates of 7.5-year
ause-specific mortality rates are shown in Figure 2.
atients who underwent CABG had a significantly lower
ncidence of sudden death (2.4% vs 3.9%, P  .01) but
imilar rates of deaths resulting from MI (3.2% vs 3.1%,
 .64), CHF and other cardiac causes (1.9% vs 1.9%,
 .59), and noncardiac causes (9.7% vs 9.9%, P 
84). Unadjusted competing-risks analysis demonstrated
onsistent results. Revascularization with CABG was
ssociated with a significantly lower risk of sudden car-
iac death (RR, 0.62; 95% CI, 0.42– 0.91; P  .01) but
as not associated with the other causes of death indi-
idually (MI: RR, 1.10; 95% CI, 0.75–1.61; P  .63;
HF and other cardiac causes: RR, 1.14; 95% CI, 0.70 –
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1
0
(
M
A
v
c
C
s
.
i

d
a
.
s
f
a
c
T
m
a
C
(
c
m
a
p
1
T
D
M
C
A
C
c
w
Holmes et al Surgery for Acquired Cardiovascular Disease
A
CD.87; P  .59; noncardiac causes: RR, 0.98; 95% CI,
.79 –1.22; P  .84) or these 3 causes of death combined
RR, 1.02; 95% CI, 0.86 –1.22; P  .80).
ultivariate Analyses
djusted mortality estimates are presented in Table 2. Re-
ascularization with CABG did not significantly affect all-
ause mortality (RR, 0.90; 95% CI, 0.77–1.06; P  .19).
ABG was associated with a significantly lower risk of
udden cardiac death (RR, 0.60; 95% CI, 0.41–0.88; P 
01) but was not associated with other causes of death
ndividually or combined (RR, 0.98; 95% CI, 0.82–1.17; P
.83). Moreover, the effect of CABG on sudden cardiac
eath was significantly different than the effect of CABG on
ll other causes of death combined (RR, 0.60 vs 0.98; P 
ABLE 1. Baseline characteristics by vital status and cau
Alive
(n  2989)
Sudden de
(n  10
emographic profile
Age (y) 61  10 62 9
Male sex 75 77
White race 93 82
Black race 4 12
Post–high school education 36 28
edical history
Treated diabetes 15 31
MI 51 65
CHF 5 14
Peripheral vascular disease 13 21
Hypertension 46 55
Renal dysfunction 1 7
Malignancy 4 7
linical profile
Former smoker 46 50
Current smoker 23 25
Stable angina class 1 or 2 16 10
Stable angina class 3 or 4 15 9
Unstable angina/non-Q MI 68 80
Angina duration 1 y 39 34
Major Q-waves 16 23
ST depression 5 12
Major ECG abnormality 40 54
ngiographic profile
Triple-vessel disease 37 49
Proximal LAD disease 38 38
Ejection fraction 50%† 14 28
Left-sided/mixed dominance 14 23
ategoric variables are presented as column percentages and continuou
ongestive heart failure; ECG, electrocardiographic; LAD, left anterior desc
ho died. †Ejection fraction data are missing for 462 patients.02). The multivariate model also revealed a statistically 0
The Journal of Thoracignificant interaction between CABG and diabetes status
or death caused by MI (test of interaction, P  .04) but not
ny of the other causes (sudden death, P  .92; CHF/other
ardiac causes, P  .19; noncardiac causes, P  .53).
herefore the adjusted effect of CABG on cause-specific
ortality was examined separately for nondiabetic and di-
betic patients (Table 2).
Among patients without diabetes, revascularization with
ABG significantly decreased the risk of sudden cardiac death
RR, 0.61; 95% CI, 0.38–0.97; P  .04) but did not signifi-
antly affect any other specific causes of death or overall
ortality. In patients with diabetes, CABG was associated with
32% lower risk of long-term mortality, and a trend toward a
rotective effect on sudden death (RR, 0.55; 95% CI, 0.28–
.10; P  .09) and death caused by MI (RR, 0.54; 95% CI,
f death
Dead (cause of death)
MI
(n  109)
CHF/other
cardiac
(n  68)
Noncardiac
(n  337)
P
value*
64  10 67 9 66  9 .01
63 60 68 .09
89 85 89 .31
10 10 8
26 25 29 .33
36 47 30 .04
64 62 51 .01
23 25 14 .03
26 29 29 .40
64 69 58 .20
6 12 5 .21
6 10 12 .16
40 44 47 .52
27 21 26
13 12 13 .27
16 24 15
72 65 71
55 43 49 .01
25 22 23 .96
8 21 6 .01
52 54 52 .97
46 49 40 .28
43 25 40 .12
24 34 20 .02
26 12 17 .06
riables as means  standard deviation. MI, Myocardial infarction; CHF,
g coronary artery. *P values compare 4 causes of death among patientsse o
ath
7)
s va
endin.28–1.02; P  .06) was observed. Revascularization with
ic and Cardiovascular Surgery ● Volume 134, Number 1 41
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CDABG was not associated with CHF-related or noncardiac
ortality among diabetic patients.
urther Examination of Sudden Cardiac and MI-
elated Deaths
he effect of CABG on sudden death and MI-related death
ver time stratified by diabetes status is shown in Figures 3
nd 4. Among patients without diabetes, the cumulative
udden death rate curves diverged steadily over time and,2 The Journal of Thoracic and Cardiovascular Surgery ● July 2.5 years after initial revascularization, were significantly
ower in patients who underwent CABG versus those who
id not (2.0% vs 3.3%, P  .04). A similar protective effect
as observed in patients with diabetes, with sudden death
ates of 4.4% and 7.7% (P  .08) at 7.5 years in the CABG
nd no-CABG groups, respectively. In patients without
iabetes, MI-related mortality occurred more frequently in
he CABG group in the first month; however, during 7.5
ears of follow-up, the cumulative rates converged such that
Figure 1. Kaplan–Meier curves for car-
diac and noncardiac death by coronary
artery bypass grafting (CABG) status.
Figure 2. Cumulative rates at 7.5 years
for specific causes of death by coro-
nary artery bypass grafting (CABG) sta-
tus. MI, Myocardial infarction; CHF,
congestive heart failure.007
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CDhe MI-related death rate was 2.7% in the CABG group and
.0% in the no-CABG group (P  .10). In contrast, among
atients with diabetes, the MI-related death rate was slightly
igher in the CABG group during the first 2 years, but by
.5 years, the cumulative MI-related death rate was signif-
cantly lower in patients who underwent CABG compared
ith the rate in those who did not (5.4% vs 10.2%, P .04).
iscussion
ABG had differential effects on various causes of long-
erm mortality in the BARI cohort of revascularized pa-
ients. Revascularization with CABG significantly de-
reased the risk of sudden cardiac death but did not affect
ther causes of death. Furthermore, the protective effect of
ABG against sudden death was observed in patients re-
ardless of diabetes status.
Why might CABG reduce the risk of sudden cardiac
eath? Although the mechanism of sudden death in the
etting of CAD is complex, it commonly occurs secondary
o ventricular tachyarrhythmia16,17 (which often degenerates
nto ventricular fibrillation18) triggered by myocardial isch-
mia.19 In general, patients receiving CABG are more com-
letely revascularized and have the advantage of a greater
elief of myocardial jeopardy than those undergoing percu-
aneous intervention, which targets a more limited extent of
 given coronary artery.20 Although this approach to percu-
aneous coronary intervention (PCI) does not appear to
ompromise overall survival, as per BARI in those without
reated diabetes, the current study indicates that PTCA, as
erformed between 1988 and 1991, left patients at risk for
udden death in contrast to revascularization with CABG.
hus, we suggest that patients in BARI who received
ABG had greater and more durable protection against MI,
hich preferentially protected against acute environmental
vents that might heighten susceptibility to ventricular ar-
ABLE 2. Relative risk associated with coronary artery
ortality
All patients (n  3610)
No. of
events RR* 95% CI
P
valu
ffect of CABG (vs no CABG) on:
All-cause mortality 621 0.90 0.77–1.06 .19
Sudden cardiac death† 107 0.60 0.41–0.88 .01
MI death‡ 109 1.06 0.72–1.56 .76
CHF/other cardiac death 68 1.10 0.67–1.79 .72
Noncardiac death 337 0.93 0.75–1.16 .54
R, Relative risk; 95% CI, 95% confidence interval; CABG, coronary arte
Adjusted for diabetes, age, sex, race, smoking, congestive heart failur
isease, renal dysfunction, left/mixed dominance, ejection fraction, and ma
udden cardiac death was significantly different than on all other causes
ypass grafting on myocardial infarction–related death was significantly dhythmia. This is further supported by the CABG-Patch g
The Journal of Thoracrial, which indicated that bypass surgery was protective
gainst sudden death, such that cardiac defibrillator implan-
ation did not confer additional benefit.21
Our results might have important clinical implications
or guiding CAD treatment strategies. Specifically, CABG
ight be the preferred method of revascularization in pa-
ients who are identified as having an increased risk of
udden cardiac death because of extensive CAD,6,22 a his-
ory of ventricular arrhythmia,23 ECG abnormalities, and
mpaired left ventricular function.24 Consistent with prior
tudies, patients who died suddenly in BARI were more
ikely to have EFs of less than 50%, diabetes, history of MI,
riple-vessel disease, unstable angina, and abnormalities on
esting ECG. If PCI is the intervention ultimately chosen in
his high-risk subset, a more complete revascularization
ight be wise. Prior studies in the Coronary Artery Surgery
tudy emphasized the importance of complete surgical re-
ascularization in patients with decreased left ventricular
unction. Patients who are not suitable candidates for bypass
urgery might benefit from added measures to prevent sud-
en death, such as prophylactic use of an implantable car-
iac defibrillator, which has been shown to substantially
mprove survival in the CAD population by preventing
udden death.25
Of note, PTCA in BARI preceded the routine use of both
are-metal and drug-eluting stents, and similarly, CABG
as continually progressed with improved perioperative
anagement, more frequent use of arterial grafting, and
mproved techniques with minimally invasive and off-pump
perations as options.26,27 In the context of these develop-
ents, are the BARI results relevant? Yes. As described
bove, the subset of patients who benefited most from
ABG were those at high risk of sudden cardiac death as
haracterized by extensive CAD, decreased left ventricular
unction, and abnormalities on the resting electrocardio-
ss grafting for overall and specific causes of long-term
No diabetes (n  2968) Diabetes (n  642)
o. of
vents RR* 95% CI
P
value
No. of
events RR* 95% CI
P
value
416 1.01 0.83–1.23 .94 205 0.68 0.52–0.90 .01
74 0.61 0.38–0.97 .04 33 0.55 0.28–1.10 .09
70 1.51 0.92–2.46 .10 39 0.54 0.28–1.02 .06
36 1.49 0.74–2.99 .26 32 0.69 0.34–1.39 .30
236 0.99 0.77–1.29 .96 101 0.80 0.54–1.19 .27
pass grafting; MI, myocardial infarction; CHF, congestive heart failure.
pertension, major electrocardiographic abnormality, peripheral vascular
ncy. †Among all patients, the effect of coronary artery bypass grafting on
th combined (test of interaction, P  .02). ‡The effect of coronary artery
nt in nondiabetic and diabetic patients (test of interaction, P  .04).bypa
e
N
e
ry by
e, hy
ligna
of dearam, for example. By way of analogy, PCI is currently
ic and Cardiovascular Surgery ● Volume 134, Number 1 43
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CDhallenging CABG as an alternative for revascularization of
igh-risk patients with triple-vessel disease or left main
isease, domains historically reserved for CABG. Whether
urrent methods of PCI will eliminate or minimize the
istorical advantage of CABG in selected high-risk subsets
s under study in several current large randomized trials. To
his end, our data corroborate the need for rigorous evalu-
tion of revascularization strategy of very high-risk patients,
n particular those at high risk of sudden cardiac death.
Multivariate analysis of cause-specific mortality also re-
ealed that the effect of CABG on MI-related death was
odified by diabetes status. For the relative effect of bypass
urgery on MI-related mortality, the stratified models dem-4 The Journal of Thoracic and Cardiovascular Surgery ● July 2nstrated a trend toward an increased risk in patients with-
ut diabetes and a decreased risk in those with diabetes.
urthermore, the effect of CABG on MI-related death dif-
ered significantly in the presence versus absence of diabe-
es. This is consistent with the previous report by Detre and
olleagues28 that demonstrated that among revascularized
atients who have an MI, CABG offered greater protection
gainst long-term mortality in diabetic patients compared
ith nondiabetic patients.
The purpose of this analysis was to evaluate the effect of
eceiving CABG on various causes of mortality and not to
valuate the strategy of initial revascularization with CABG
ersus PTCA, which is best accomplished in an intent-to-
Figure 3. Kaplan–Meier curves for
sudden cardiac death comparing cor-
onary artery bypass grafting (CABG)
versus no CABG stratified by diabetes
status.
Figure 4. Kaplan–Meier curves for
myocardial infarction–related death
comparing coronary artery bypass
grafting (CABG) versus no CABG strat-
ified by diabetes status.007
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A
CDreat analysis of a randomized clinical trial. Because BARI
egistry patients met every eligibility criteria for the ran-
omized trial except a willingness to be randomly assigned
o treatment, our purpose was best served by including both
he randomized and registry cohorts in this analysis and by
onsidering treatment with CABG at any time during the
ARI study as our key covariate. The same patient sample
nd methodology were used in the BARI report by Detre
nd colleagues28 to evaluate the effect of CABG on survival
fter an MI.
All-cause mortality is a common end point in clinical
tudies because death, regardless of its cause, is a critical
nd meaningful outcome, especially when evaluating treat-
ents designed to prolong survival. From a methodologic
erspective, clearly defined end points are more easily ver-
fied, and the data are more often complete. Despite such
dvantages, important implications of the disease process
nd treatment effect might be missed by ignoring cause-
pecific death. Holmes and associates4 reported that the
atio of cardiac to noncardiac deaths tends to decrease as
atients age within a study cohort and as follow-up time
ncreases. A preponderance of noncardiac deaths might
bscure accurate interpretation of studies investigating
ong-term treatment effects, particularly in an aging patient
opulation.
This study has the limitations of an observational
tudy, as well as the difficulty of establishing the actual
ause of death. A strength of the BARI study, however,
s the manner in which cause of death was determined.
n independent morbidity and mortality committee com-
rised of cardiologists was included in the original BARI
esign, and the initial 5-year results showing a survival
enefit with CABG in patients with diabetes was greatly
nhanced by determining that the difference was entirely
ue to cardiac mortality.
onclusions
valuation of cause-specific mortality provided additional
nformation beyond standard analysis of all-cause or cardiac
ortality. In BARI, CABG had different effects on specific
auses of long-term mortality in patients with multivessel
AD. Revascularization with CABG significantly de-
reased the risk of sudden cardiac death, regardless of
iabetes status, while not significantly affecting the risk of
ther causes of death. Evaluation of specific causes of death
rovides insights that might be useful for guiding treatment
election and developing strategies to improve long-term
urvival after coronary revascularization.
eferences
1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the
world: Global Burden of Disease Study. Lancet. 1997;349:1269-76.
The Journal of Thorac2. The Bypass Angioplasty Revascularization Investigation (BARI) In-
vestigators. Comparison of coronary bypass surgery with angioplasty
in patients with multivessel disease. N Engl J Med. 1996;335:217-25.
3. Coronary angioplasty versus coronary artery bypass surgery: the Ran-
domized Intervention Treatment of Angina (RITA) trial. Lancet. 1993;
341:573-80.
4. Holmes DR Jr, Kip KE, Kelsey SF, Detre KM, Rosen AD. Cause of
death analysis in the NHLBI PTCA Registry: results and consider-
ations for evaluating long-term survival after coronary interventions.
J Am Coll Cardiol. 1997;30:881-7.
5. King SB 3rd, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS.
Eight-year mortality in the Emory Angioplasty versus Surgery Trial
(EAST). J Am Coll Cardiol. 2000;35:1116-21.
6. Holmes DR Jr, Davis KB, Mock MB, et al. The effect of medical and
surgical treatment on subsequent sudden cardiac death in patients with
coronary artery disease: a report from the Coronary Artery Surgery
Study. Circulation. 1986;73:1254-63.
7. Hammermeister KE, DeRouen TA, Murray JA, Dodge HT. Effect of
aortocoronary saphenous vein bypass grafting on death and sudden
death. Comparison of nonrandomized medically and surgically treated
cohorts with comparable coronary disease and left ventricular func-
tion. Am J Cardiol. 1977;39:925-34.
8. Vismara LA, Miller RR, Price JE, Karem R, DeMaria AN, Mason DT.
Improved longevity due to reduction of sudden death by aortocoronary
bypass in coronary atherosclerosis. Am J Cardiol. 1977;39:919-24.
9. Seven-year outcome in the Bypass Angioplasty Revascularization
Investigation (BARI) by treatment and diabetic status. J Am Coll
Cardiol. 2000;35:1122-9.
0. Influence of diabetes on 5-year mortality and morbidity in a random-
ized trial comparing CABG and PTCA in patients with multivessel
disease: the Bypass Angioplasty Revascularization Investigation
(BARI). Circulation. 1997;96:1761-9.
1. Protocol for the Bypass Angioplasty Revascularization Investigation.
Circulation. 1991;84:V1-27.
2. Mantel N, Byar DP. Evaluation of response-time data involving tran-
sient states: an illustration using heart-transplant data. J Am Stat Assoc.
1974;69:81-6.
3. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate
incomplete failure time data by modeling marginal distributions. J Am
Stat Assoc. 1989;84:1065-73.
4. Brooks MM, Jones RH, Bach RG, et al. Predictors of mortality and
mortality from cardiac causes in the bypass angioplasty revasculariza-
tion investigation (BARI) randomized trial and registry. Circulation.
2000;101:2682-9.
5. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:
187-220.
6. Kempf FC Jr, Josephson ME. Cardiac arrest recorded on ambulatory
electrocardiograms. Am J Cardiol. 1984;53:1577-82.
7. Liberthson RR, Nagel EL, Hirschman JC, Nussenfeld SR. Prehospital
ventricular defibrillation. Prognosis and follow-up course. N Engl
J Med. 1974;291:317-21.
8. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac
death: mechanisms of production of fatal arrhythmia on the basis of
data from 157 cases. Am Heart J. 1989;117:151-9.
9. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions
in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137-40.
0. Alderman EL, Kip KE, Whitlow PL, et al. Native coronary disease
progression exceeds failed revascularization as cause of angina after
five years in the Bypass Angioplasty Revascularization Investigation
(BARI). J Am Coll Cardiol. 2004;44:766-74.
1. Bigger JT, The Coronary Artery Bypass Graft Patch Trial I. Prophy-
lactic use of implanted cardiac defibrillators in patients at high risk for
ventricular arrhythmias after coronary-artery bypass graft surgery.
N Engl J Med. 1997;337:1569-75.
2. Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T.
Precursors of sudden coronary death. Factors related to the incidence
of sudden death. Circulation. 1975;51:606-13.
3. Chiang BN, Perlman LV, Ostrander LD Jr, Epstein FH. Relation-
ship of premature systoles to coronary heart disease and sudden
death in the Tecumseh epidemiologic study. Ann Intern Med.
1969;70:1159-66.
ic and Cardiovascular Surgery ● Volume 134, Number 1 45
22
2
2
2
Surgery for Acquired Cardiovascular Disease Holmes et al
4
A
CD4. Sanz G, Castaner A, Betriu A, et al. Determinants of prognosis in
survivors of myocardial infarction: a prospective clinical angiographic
study. N Engl J Med. 1982;306:1065-70.
5. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an
implanted defibrillator in patients with coronary disease at high risk for
ventricular arrhythmia. Multicenter Automatic Defibrillator Implanta-
tion Trial Investigators. N Engl J Med. 1996;335:1933-40.
6. Nishida H, Tomizawa Y, Endo M, Kurosawa H. Survival benefit of
exclusive use of in situ arterial conduits over combined use of arterial
and vein grafts for multiple coronary artery bypass grafting. Circula-6 The Journal of Thoracic and Cardiovascular Surgery ● July 27. Ferguson TB Jr, Hammill BG, Peterson ED, DeLong ER, Grover
FL. A decade of change—risk profiles and outcomes for isolated
coronary artery bypass grafting procedures, 1990-1999: a report
from the STS National Database Committee and the Duke Clinical
Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg.
2002;73:480-90.
8. Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous
coronary artery bypass surgery on the prognosis of patients with
diabetes who have acute myocardial infarction. Bypass Angioplasty
Revascularization Investigation Investigators. N Engl J Med. 2000;tion. 2005;112(suppl):I299-303. 342:989-97.007
Holmes et al Surgery for Acquired Cardiovascular Disease
A
CDFigure E1. Vital status and cause of death (among patients who died) over an average of 7.7 years of follow-up after
initial revascularization. MI, Myocardial infarction; CHF, congestive heart failure.The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 1 46.e1
